Coherus Oncology, Inc. (CHRS) vs Organogenesis Holdings Inc. (ORGO)
A side-by-side comparison of Coherus Oncology, Inc. and Organogenesis Holdings Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.05HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
ORGO
Organogenesis Holdings Inc.
$1.32HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
Total return — CHRS vs ORGO
growth of $100 · dividends reinvested · last 10yCHRS -96.1% (-27.8%/yr)ORGO -86.8% (-18.3%/yr)ORGO compounded faster over this window
CHRS ORGO
CHRS vs ORGO: by the numbers
- •ORGO is the larger company ($170M vs $162M market cap).
- •Both run net losses; ORGO's is the smaller (-19.76% vs -257.10% net margin).
- •ORGO grew revenue faster over the past five years (1.05% vs -33.60% CAGR).
Metrics side by side
Valuation
| Metric | CHRS | ORGO |
|---|---|---|
| P/S ratio | 3.18 | 0.37 |
| P/B ratio | 2.67 | 1.15 |
| EV / EBITDA | N/A | 214.03 |
| FCF yield | N/A | 12.27% |
Profitability
| Metric | CHRS | ORGO |
|---|---|---|
| Gross margin | 63.55% | 67.59% |
| Operating margin | -425.72% | 9.92% |
| Net margin | -257.10% | -19.76% |
| ROE | -215.26% | -31.32% |
| ROIC | -135.38% | -8.34% |
Growth (annualized)
| Metric | CHRS | ORGO |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | 1.05% |
| FCF CAGR (5Y) | N/A | -5.54% |
| Total return CAGR (5Y) | -41.38% | -37.41% |
Frequently asked
- Which has grown faster, CHRS or ORGO?
- Over the past five years, ORGO grew revenue faster — CHRS at a -33.60% CAGR versus ORGO at 1.05%.
- How have CHRS and ORGO total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and ORGO delivered -37.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Coherus Oncology ROEOrganogenesis ROECoherus Oncology operating marginOrganogenesis operating marginCoherus Oncology revenue growthOrganogenesis revenue growthCoherus Oncology free cash flowOrganogenesis free cash flow
Coherus Oncology & Organogenesis appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.